• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

byStudy Graphics | C.WuandConstance Wu
September 6, 2020
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

1. Pelvic and paraaortic lymphadenectomy in advanced ovarian cancer patients provided no overall or progression-free survival benefits compared to patients not undergoing lymphadenectomy.

2. Serious postoperative complications, including postoperative death, occurred at greater rates in patients undergoing systematic lymphadenectomy.

Evidence Rating Level: 1 (Excellent)    

Study Rundown: Patients with advanced ovarian cancer generally receive surgery to remove all macroscopically visible tumor followed by chemotherapy. Some studies have suggested systematic pelvic and paraaortic lymphadenectomy provides additional survival benefit in these patients. The Lymphadenectomy in Ovarian Neoplasms (LION) trial sought to evaluate the survival benefit of systematic lymphadenectomy in patients with gross resection of advanced ovarian neoplasm. The median overall and progression-free survival rates did not differ between the groups receiving and not receiving lymphadenectomy, and patients undergoing lymphadenectomy experienced significantly greater postoperative complication rates.

This study provides compelling evidence that after complete macroscopic tumor resection, further lymphadenectomy in advanced ovarian cancer patients is unnecessarily morbid and provides no survival advantage. A limitation of this trial is generalizability as patients were treated at specialized surgical centers.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

Tags: lymphadenectomyovarian cancer
Previous Post

Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series

Next Post

Tramadol may be associated with increased mortality among patients with osteoarthritis

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality

July 18, 2021
Next Post
Placebo formulation impacts effectiveness of pain control in osteoarthritis

Tramadol may be associated with increased mortality among patients with osteoarthritis

High risk of complications, but low mortality among children with MRSA bacteremia

Quick Take: Chlorhexidine Versus Routine Bathing to Prevent Multidrug-Resistant Organisms and All-Cause Bloodstream Infections in General Medical and Surgical Units (ABATE Infection Trial)

#VisualAbstract: Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression

#VisualAbstract: Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.